Regeneron (REGN), Sanofi (SNY) Report Dupilumab Met Primary Endpoint in Phase 2b
Tweet Send to a Friend
Regeneron Pharma. (Nasdaq: REGN) and Sanofi (NYSE: SNY) announced positive results from a Phase 2b dose-ranging study of dupilumab, an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
